The Key Elements of Being “Recall-Ready”

20 Nis 2022 · FDA CDER Small Business and Industry Assistance (SBIA) Chronicles

00:07:51

A voluntary recall is an action taken by a company to correct a violative product or remove it from the market.

Dinle Tekrar dinle Devam et Oynatılıyor…
Abone ol Abonelikten çık
Paylaş

Bölümler

Considerations for Drug Products that Contain Nanomaterials
15 May· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Considerations for Drug Products that Contain Nanomaterials
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
Using Bayesian statistical approaches to advance our ability to evaluate drug products
18 Ağu 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Using Bayesian statistical approaches to advance our ability to evaluate drug products
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
Eksik bölüm mü var?

Akışı yenilemek için buraya tıklayın.
Insights About the FDA/EMA Parallel Scientific Advice Program for Complex Generic/Hybrid Drug Products
11 Tem 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Insights About the FDA/EMA Parallel Scientific Advice Program for Complex Generic/Hybrid Drug Products
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
10 Nis 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
7 Şub 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
29 Eyl 2022· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
An FDA Self-Audit of Continuous Manufacturing for Drug Products
28 Haz 2022· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
The Key Elements of Being “Recall-Ready”
20 Nis 2022· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
A voluntary recall is an action taken by a company to correct a violative product or remove it from the market.
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
The ABCs of Product Specific Guidances
3 Eyl 2021· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Product-specific guidances (or PSGs for short) describe the Agency's current thinking on the evidence needed to demonstrate that a generic drug is therapeutically equivalent to the corresponding reference listed drug (RLD) product.
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
Improving Regulatory Communication via the CDER NextGen Portal
19 Ara 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
Abbreviated Approval Pathways for Drug Product: 505(b)(2) or ANDA?
19 Eyl 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Abbreviated Approval Pathways for Drug Product: 505(b)(2) or ANDA? | September 19, 2019 Issue
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
Research Investigational New Drug Applications – What You Need To Know
25 Haz 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
FDA recently released an update to clarify when ‘Research’ vs. ‘Commercial’ should be selected on FDA Form 1571, and thus when electronic common technical document or “eCTD” requirements would apply for an investigational new drug or “IND” application.
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
Competitive Generic Therapies
23 May 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Competitive Generic Therapies May 23, 2019 Issue
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle
FDA Modernizes Clinical Trials with Master Protocols
26 Şub 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
"FDA Modernizes Clinical Trials with Master Protocols" February 26, 2019 Issue
- Dinle Tekrar dinle Devam et Oynatılıyor…
- Daha sonra dinle Daha sonra dinle

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.